Dmitri Bobilev - 07 Nov 2022 Form 4 Insider Report for Fusion Pharmaceuticals Inc.

Role
Chief Medical Officer
Signature
/s/Maria Stahl as Attorney-in-Fact for Dmitri Bobilev
Issuer symbol
N/A
Transactions as of
07 Nov 2022
Net transactions value
$0
Form type
4
Filing time
07 Nov 2022, 18:29:01 UTC
Next filing
05 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +550,000 $0.000000 550,000 07 Nov 2022 Common Stock 550,000 $1.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option shall vest and become exercisable on the first anniversary the grant date and the remainder shall vest and become exercisable in 36 substantially equal monthly installments thereafter.